Linked Life Data

16417467

Source:http://linkedlifedata.com/resource/pubmed/id/16417467

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-4-6
pubmed:abstractText
Novel therapies for the treatment of MOF (multiple organ failure) are required. In the present study, we examined the effect of synthetic GHRP-6 (growth hormone-releasing peptide-6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human colonic cancer (HT29) cells as in vitro models of injury. In addition, we examined its efficacy when given alone and in combination with the potent protective factor EGF (epidermal growth factor) in an in vivo model of MOF (using two hepatic vessel ischaemia/reperfusion protocols; 45 min of ischaemia and 45 min of reperfusion or 90 min of ischaemia and 120 min of reperfusion). In vitro studies showed that GHRP-6 directly influenced gut epithelial function as its addition caused a 3-fold increase in the rate of cell migration of IEC-6 and HT29 cells (P<0.01), but did not increase proliferation ([3H]thymidine incorporation). In vivo studies showed that, compared with baseline values, ischaemia/reperfusion caused marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (myeloperoxidase assay; 5-fold increase) and lipid peroxidation (malondialdehyde assay; 4-fold increase). Pre-treatment with GHRP-6 (120 microg/kg of body weight, intraperitoneally) alone truncated these effects by 50-85% (all P<0.05) and an additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/kg of body weight, intraperitoneally). Lung and renal injuries were also reduced by these pre-treatments. In conclusion, administration of GHRP-6, given alone or in combination with EGF to enhance its effects, may provide a novel simple approach for the prevention and treatment of MOF and other injuries of the gastrointestinal tract. In view of these findings, further studies appear justified.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0143-5221
pubmed:author
pubmed:issnType
Print
pubmed:volume
110
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
563-73
pubmed:dateRevised
2007-8-13
pubmed:meshHeading
pubmed-meshheading:16417467-Animals, pubmed-meshheading:16417467-Cell Movement, pubmed-meshheading:16417467-Cell Proliferation, pubmed-meshheading:16417467-Cells, Cultured, pubmed-meshheading:16417467-Dose-Response Relationship, Drug, pubmed-meshheading:16417467-Epidermal Growth Factor, pubmed-meshheading:16417467-Growth Hormone-Releasing Hormone, pubmed-meshheading:16417467-Humans, pubmed-meshheading:16417467-Intestinal Mucosa, pubmed-meshheading:16417467-Lipid Peroxidation, pubmed-meshheading:16417467-Male, pubmed-meshheading:16417467-Multiple Organ Failure, pubmed-meshheading:16417467-Neutrophil Infiltration, pubmed-meshheading:16417467-Oligopeptides, pubmed-meshheading:16417467-Rats, pubmed-meshheading:16417467-Rats, Wistar, pubmed-meshheading:16417467-Recombinant Proteins, pubmed-meshheading:16417467-Reperfusion Injury, pubmed-meshheading:16417467-Tumor Cells, Cultured
pubmed:year
2006
pubmed:articleTitle
Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.
pubmed:affiliation
Center for Genetic Engineering and Biotechnology, Ave 31 e/158 & 190 Playa 10600, Havana, Cuba.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't